We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byPriscilla Miller
Modified about 1 year ago
Azathioprine for IBD : Better the devil you know Jeremy D. Sanderson
Azathioprine for inducing remission in active IBD 425 patients (209 AZA/6-MP, 216 placebo) End-points: steroid sparing effect, clinical response Overall response Aza/6-MP54% (CI 47%-61%) placebo 33% (CI 27%-40%) Pooled OR2.36 (CI 1.57 – 3.53) Time to respondPresent 1980av. 3.1 months OR 1.54 if <17 weeks Rx OR 2.51 if >17 weeks Rx Steroid sparingAza/6-MP65% (CI 56%-74%) placebo36% (CI 27%-45%) Pooled OR3.86 (CI 2.14 – 6.96) Sandborn et al, Cochrane Library, Issue 4, 2000
Background Azathioprine effective in 70% patients with IBD 30% failure due to:Intolerance 15% No response 15% IntoleranceBone marrow suppression Nausea Myalgia, flu-like symptoms Pancreatitis Hepatotoxicity Other Azathioprine failuresMTX, anti-TNF Surgery
Azathioprine 6-Mercaptopurine 6-thioinosine nucleotide 6-thioguanine nucleotides Thiouric acid 6-Me MP TPMT*** Xanthine oxidase HGPRT IMPDH ImmunosppressionClinical benefit
Intermediate High (Normal) Very High Low
TPMT (thiopurine methyl transferase) allelic polymorphism High TPMT 89% Intermediate TPMT 11% Low TPMT 1/300 ?very high TPMT Severe Bone Marrow Suppression !! High risk of marrow suppression Low risk ? poor responders - + clinical response
Initiate at 100mg Build to 2mg/kg AZA treatment ? Check TPMT Enzyme / genotype Check TPMT Enzyme / genotype Homozygous deficient Heterozygous deficient Normal Initiate at 25mg Build to 1mg/kg Consider 2.5 – 5mg AZA ? Thioguanine Alternative Rx Consider 2.5 – 5mg AZA ? Thioguanine Alternative Rx TolerantIntolerant Very high Flu-like illness Pancreatitis Hepatitis Flu-like illness Pancreatitis Hepatitis Nausea Reduce dose Switch to 6-MP Alternative Rx ? Thioguanine Marrow suppression Reduce dose Check for drugs, 5’-nucleotidase def Parvovirus infection Repeat TPMT 6mo – 1yr. InducedNo change Increase AZAContinue Initiate at 100mg Build to 2.5 – 3mg/kg Non-response…...
Bargain Azathioprine …….. still the best and getting better
IBD medical therapy …… …… the Bridge approach
Crohn’s disease : the Bridge approach Antibiotics Nutritional Rx Steroids Methotrexate Anti-TNF Azathioprine Mycophenolate ?? Methotrexate
Conclusions Many new and potentially exciting therapies for refractory IBD But before you use them …….. Make sure you get the best out of existing approaches
Natalizumab- Unmet Need in the Management of Crohn’s Disease Doug Wolf, M.D. Atlanta Gastroenterology Associates July 31, 2007.
Thiopurines still have a role in the management of pediatric IBD Athos Bousvaros MD, MPH Associate Director, IBD program Boston Children’s Hospital.
Methotrexate Indications and Approaches Hans Herfarth, MD, PhD University of North Carolina at Chapel Hill Chapel Hill, North Carolina.
6-MP and AZA Applications and Approaches Marla Dubinsky, MD Chief, Pediatric GI and Hepatology Co-Director, Susan and Leonard Feinstein IBD Clinical Center.
When can we use combination therapy for our pediatric IBD patients? Athos Bousvaros MD, MPH Advances in IBD Dec 2014.
Immunomodulators and Biologics Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida.
Colitis in the Very Young. Case 8 month old presented with bloody bowel movements and diarrhea Maternal history of UC Endoscopy – pan colitis Infectious.
You Can Never Stop a Biologic Scott D Lee MD Associate Professor of Medicine Director, Clinical Inflammatory Bowel Diseases Program University of Washington.
Immunosuppressive Medications and IBD: Now and What’s Next Stephen B. Hanauer, MD University of Chicago.
Inflammatory Bowel Disease Treatment. Epidemiology Clinical Laboratory Imaging Pathology Response to treatment IBD.
Early Administration of Azathioprine Versus Conventional Management of Crohn’s Disease : A Randomized Controlled Trial F1. Ja Won Koo JACQUES COSNES, ANNE.
Hepatitis web study Hepatitis web study Boceprevir in Treatment Experienced RESPOND-2 Phase 3 Treatment Experienced Bacon BR, et al. N Engl J Med. 2011;364:
Treatment of Vasculitis: immunesuppressives and biologics David Jayne Vasculitis and Lupus Clinic Addenbrooke’s Hospital Cambridge UK BSR Course, Oxford,
Clinical Vignette: Medical Grand Rounds Joshua L. Denson MD Internal Medicine PGY2 January 7, 2013 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Improving outcome of Inflammatory Bowel Disease in children Dinesh Pashankar, MD Pediatric Gastroenterologist Director- Pediatric IBD program Yale University.
Emerging treatments in Crohn’s disease and ulcerative colitis Athos Bousvaros MD MPH Boston Children’s Hospital.
Pro: All medications may be stopped for Crohn’s disease patients in remission Miguel Regueiro, M.D. Professor of Medicine Associate Chief for Education.
Monotherapy using 6-MP or azathioprine for Crohn’s disease is dead: out with the old and in with the new Stephen B. Hanauer, MD Professor of Medicine Clinical.
Inflammatory Bowel Disease Kimberly Persley, MD Digestive Disease Associates of Dallas Presbyterian Hospital of Dallas.
IBD Cases Stephen B. Hanauer, MD Professor of Medicine Feinberg School of Medicine Medical Director, Digestive Health Center.
“Antibiotics and corticosteroids: Indications and approaches” Raymond Cross, M.D., M.S., AGAF Associate Professor of Medicine Director of the Inflammatory.
Medical Management of Ulcerative Colitis Conrad Beckett Bradford Royal Infirmary M62 Course March 2006.
Medications should never be stopped for Crohn’s disease patients in remission Thomas Ullman, M.D. Chief Medical Officer Mount Sinai Doctors Faculty Practice.
Medical Management of Ulcerative Colitis Alistair Makin Manchester Royal Infirmary.
Recent advances in medical treatment of inflammatory bowel disease Adrian Thomas, Booth Hall Childrens Hospital Manchester, M9 7AA, UK.
Therapy of Inflammatory Bowel Diseases 2013 Gastroenterology Department Division of Medicine Eran Israeli MD.
Presented at the Arthritis Advisory Committee on July 15, 2003 by Naomi Winick, M.D.
1 Unconventiional Therapies: What to do when all else fails? Scott Plevy, MD Associate Professor of Medicine, Microbiology & Immunology UNC School of Medicine.
Asymptomatic UC patients on an immunomodulator with persistent moderate mucosal inflammation should either add a biologic or switch to a biologic William.
Vedolizumab in Pediatric IBD: We are Ready to Use It Ted Denson, MD Cincinnati Children’s Hospital Medical Center University of Cincinnati College of Medicine.
1 Benefit-Risk of Crohn’s Disease Therapeutics William Sandborn, MD Mayo Clinic and Mayo College of Medicine Rochester, MN, USA.
Hepatitis web study Hepatitis web study Sofosbuvir in Genotypes 2 or 3 VALENCE Trial Phase 3 Treatment Naïve and Treatment Experienced Zeuzem S, et al.
Therapeutic algorithms for Crohn’s disease: Where are we in 2012?
Aminosalicylates in IBD: New Data on an Old Therapy Joel R. Rosh, MD Director, Pediatric Gastroenterology Goryeb Children’s Hospital/Atlantic Health Professor.
CZ5225 Methods in Computational Biology Lecture 9: Pharmacogenetics and individual variation of drug response CZ5225 Methods in Computational Biology.
Autoimmune Hepatitis Overview Diagnosis & Treatment.
Medical therapy decisions for the difficult to treat IBD patient and the nursing role. Case Study Advances 2014 Betty White C-NP Manager Center for Crohn’s.
Am J Gastroenterol 2010; 105:1820–1829 F1 박재현. Background Background A novel mouse line with defects in both transforming growth factor- β type II receptor.
Should we change how we position biologics in ulcerative colitis? Bruce E. Sands, MD, MS Chief of the Dr. Henry D. Janowitz Division of Gastroenterology.
Management of Inflammatory bowel disease 8/12/10.
Pharmacogenetics (PGx) of Irinotecan: Scientific and Clinical Impact of UGT Polymorphism: Background Clinical Pharmacology Subcommittee of ACPS November.
(Date of presentation) (Name of presenter) UK IBD audit Biological therapies audit 2014 Comparison of (Your site name) results against the national results.
Who should receive early anti-TNF therapy: With what benefits and risks? Ted Denson, MD Cincinnati Childrens Hospital Medical Center University of Cincinnati.
Planning for Biosimilars: Infliximab Professor Ray Fitzpatrick Secondary Care lead Keele University Clinical Director of Pharmacy Royal Wolverhampton NHS.
Prevention of Postoperative Crohn’s disease Miguel Regueiro, M.D. Professor of Medicine Associate Chief for Education Clinical Head and Co-Director, IBD.
The Patient With Pyoderma Gangrenosum Maria T. Abreu, MD Chief, Division of Gastroenterology University of Miami Miller School of Medicine Miami, Florida.
Pediatric IBD Research STAKEHOLDER REVIEWER TRAINING PROGRAM Michael D. Kappelman, M.D.,M.P.H. Pediatric Gastroenterology, and Center for GI Biology and.
Understanding Contraindications to the Use of Immunomodulators and Biologics for Inflammatory Bowel Disease Edward V. Loftus, Jr., M.D. Professor of Medicine.
State of the Art Management of Crohn ’ s Disease Talal Al-Taweel Haya Al-Habeeb Gastroenterology Center Mubarak Al-Kabeer Hospital March 2015.
Hepatitis web study Hepatitis web study Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial Phase 2a Treatment Naïve and Treatment.
© 2017 SlidePlayer.com Inc. All rights reserved.